These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 31414143)

  • 1. The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice.
    Hutch CR; Roelofs K; Haller A; Sorrell J; Leix K; D'Alessio DD; Augustin R; Seeley RJ; Klein T; Sandoval DA
    Diabetologia; 2019 Oct; 62(10):1928-1937. PubMed ID: 31414143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.
    Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N
    Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice.
    Bhat VK; Kerr BD; Vasu S; Flatt PR; Gault VA
    Diabetologia; 2013 Jun; 56(6):1417-24. PubMed ID: 23503814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Yokoyama H; Haneda M
    Front Endocrinol (Lausanne); 2020; 11():214. PubMed ID: 32390941
    [No Abstract]   [Full Text] [Related]  

  • 6. A Quantitative Systems Pharmacology Model of the Incretin Hormones GIP and GLP1, Glucagon, Glucose, Insulin, and the Small Molecule DPP-4 Inhibitor, Linagliptin.
    Wu N; An G
    J Pharm Sci; 2024 Jan; 113(1):278-289. PubMed ID: 37716531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPP-4 inhibition increases GIP and decreases GLP-1 incretin effects during intravenous glucose tolerance test in Wistar rats.
    Freyse EJ; Berg S; Kohnert KD; Heinke P; Salzsieder E
    Biol Chem; 2011 Mar; 392(3):209-15. PubMed ID: 21281062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of endogenous GLP-1 and GIP on glucose tolerance after Roux-en-Y gastric bypass surgery.
    Svane MS; Bojsen-Møller KN; Nielsen S; Jørgensen NB; Dirksen C; Bendtsen F; Kristiansen VB; Hartmann B; Holst JJ; Madsbad S
    Am J Physiol Endocrinol Metab; 2016 Apr; 310(7):E505-14. PubMed ID: 26786780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
    Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
    Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice.
    Kanda J; Furukawa M; Izumo N; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
    Drug Discov Ther; 2020 Nov; 14(5):218-225. PubMed ID: 33116039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effects of linagliptin on intact and total glucagon-like peptide-1 and gastric inhibitory polypeptide levels in insulin-dependent type 2 diabetes patients with and without moderate renal impairment.
    Meier JJ; Quast DR; Nauck MA; Schenker N; Deacon CF; Holst JJ; Plum-Mörschel L; Kapitza C
    Diabetes Obes Metab; 2022 May; 24(5):806-815. PubMed ID: 34984794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.
    Deacon CF; Wamberg S; Bie P; Hughes TE; Holst JJ
    J Endocrinol; 2002 Feb; 172(2):355-62. PubMed ID: 11834453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of GIP and the contribution of GIP to the glucose-lowering properties of DPP-4 inhibitors.
    Deacon CF
    Peptides; 2020 Mar; 125():170196. PubMed ID: 31706956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
    Aaboe K; Akram S; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2015 Jan; 17(1):74-81. PubMed ID: 25243647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for neural contribution to islet effects of DPP-4 inhibition in mice.
    Ahlkvist L; Omar B; Pacini G; Ahrén B
    Eur J Pharmacol; 2016 Jun; 780():46-52. PubMed ID: 26997369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
    Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
    Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of dipeptidyl peptidase-4 augments insulin secretion in response to exogenously administered glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, pituitary adenylate cyclase-activating polypeptide, and gastrin-releasing peptide in mice.
    Ahrén B; Hughes TE
    Endocrinology; 2005 Apr; 146(4):2055-9. PubMed ID: 15604213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes.
    Stensen S; Gasbjerg LS; Rosenkilde MM; Vilsbøll T; Holst JJ; Hartmann B; Christensen MB; Knop FK
    Diabetes; 2022 Oct; 71(10):2209-2221. PubMed ID: 35796651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
    Shah P; Ardestani A; Dharmadhikari G; Laue S; Schumann DM; Kerr-Conte J; Pattou F; Klein T; Maedler K
    J Clin Endocrinol Metab; 2013 Jul; 98(7):E1163-72. PubMed ID: 23633194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.